ASH 2022 | Selecting patients for autologous transplantation in AL amyloidosis: current practice & challenges
Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, comments on patient eligibility for autologous stem cell transplantation (autoSCT) in light chain (AL) amyloidosis. Dr Wechalekar explains that there is currently a debate as to whether all patients who have a good response to frontline treatment with Dara-CyBorD (daratumumab + cyclophosphamide, bortezomib, and dexamethasone) should undergo autoSCT due to the risk of mortality associated with this treatment. Dr Wechalekar further specifies the criteria used to select patients for autoSCT and explains that patients with high-risk cytogenetics or who relapse early may benefit from autoSCT. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Honoraria, Other: Travel Support; Attralus: Honoraria; Takeda: Other: Travel Support; Alexion: Honoraria, Other: Travel Support; GSK: Honoraria.
